AbCellera Biologics Inc. (ABCL)
NasdaqGS · USD · Healthcare · Biotechnology
$12.08 (+2.20%) as of
Key statistics
- Market cap
- 3.91B
- Forward P/E
- -15.84
- EPS (TTM)
- -0.54
- Dividend yield
- 0.00%
- 52-week range
- 2.74 – 15.02
- Beta
- 1.41
- Revenue (TTM)
- 66.17M
- Profit margin
- -248.84%
- Analyst target
- $16.82
- Volume
- 3.03M
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Vancouver, BC, Canada
- Employees
- 562
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.